How has been the historical performance of Nath Bio-Genes?

Answer:The historical performance of Nath Bio-Genes shows a steady increase in net sales and profitability over the past four years, with net sales rising from 278.36 Cr in Mar'22 to 364.91 Cr in Mar'25. The total operating income followed a similar trend, reaching 364.91 Cr in Mar'25, up from 278.36 Cr in Mar'22. The company's total expenditure also increased, amounting to 315.11 Cr in Mar'25, which reflects higher manufacturing and selling expenses. Operating profit, excluding other income, remained relatively stable around 49.80 Cr in Mar'25, slightly down from 49.86 Cr in Mar'24. Profit before tax showed a positive trend, increasing to 40.04 Cr in Mar'25 from a loss of 63.43 Cr in Mar'22, while profit after tax reached 38.06 Cr in Mar'25, up from a loss of 67.39 Cr in Mar'22. The earnings per share (EPS) were reported at 20.32 in Mar'25, demonstrating a recovery from a negative EPS of -35.46 in Mar'22. The company's cash flow from operating activities also improved, with a cash flow of 74.00 Cr in Mar'24, indicating a strong operational performance.

Breakdown:
Nath Bio-Genes has demonstrated significant growth in its financial metrics over the years. Net sales increased from 278.36 Cr in Mar'22 to 364.91 Cr in Mar'25, reflecting a consistent upward trend in revenue generation. Total operating income mirrored this growth, reaching 364.91 Cr in Mar'25. Despite rising total expenditures, which reached 315.11 Cr in Mar'25, the company maintained a stable operating profit, with a slight decrease to 49.80 Cr. The profit before tax improved markedly from a loss of 63.43 Cr in Mar'22 to a profit of 40.04 Cr in Mar'25, while profit after tax also showed a positive trajectory, reaching 38.06 Cr. The earnings per share (EPS) further highlight this recovery, moving from -35.46 in Mar'22 to 20.32 in Mar'25. Additionally, cash flow from operating activities increased significantly, indicating robust operational efficiency and financial health.